To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: Vabametkib
DRUG: Lazertinib

Sponsor

Abion Inc